Intracytoplasmic sperm injection (ICSI) is a procedure that is used to help couples with fertility problems achieve parenthood. Initially developed for couples with severely diminished sperm counts, 1 it is increasingly used as the method of choice for couples with fertility problems who are undergoing in-vitro fertilisation (IVF) treatment, despite the available data suggesting that IVF is superior to ICSI in couples with normal sperm counts.
Intracytoplasmic sperm injection (ICSI) is a procedure that is used to help couples with fertility problems achieve parenthood. Initially developed for couples with severely diminished sperm counts, 1 it is increasingly used as the method of choice for couples with fertility problems who are undergoing in-vitro fertilisation (IVF) treatment, despite the available data suggesting that IVF is superior to ICSI in couples with normal sperm counts. 2 ICSI differs from IVF in that a single sperm is selected by a trained embryologist and directly injected into the oocyte, rather than letting fertilisation take place unaided after adding a few thousand motile sperm to a single oocyte. Traditionally, sperm selection is done by visual inspection at about 200 times magnification; sperm that show progressive motility and normal morphology are selected for injection. An alternative method to select sperm for ICSI is the so-called physiological, hyaluronan-based selection (PICSI) method, in which processed semen is allowed to bind to hyaluronan, and sperm that bind to hyaluronan are selected for injection. 3 Hyaluronan is a biologically active molecule that is also a major
Evidence-based medicine and infertility treatment
See Articles page 416 0·5% per year per mmol/L decrease in LDL cholesterol. This risk reduction would be expected to be higher in high-risk patients. The present meta-analysis 7 makes a case to reduce LDL cholesterol in people at risk of cardiovascular events regardless of age, provided that the benefits outweigh the risks and the patient accepts long-term treatment.
There are limitations in this meta-analysis. 7 First, patients in trials are highly selected, with fewer comorbidities, less drug intolerance, and better adherence than the general patient population. Second, the mean age of the trial participants was 63 years, and only 14 483 (8%) of 147 242 participants were older than 75 years. Third, the included clinical trials concentrated on efficacy endpoints-adverse events, especially if non-serious, were not as fully recorded and analysed, which limited the ability of this meta-analysis to develop insights into the risks of side-effects for older people with statins. Last, not all relevant trials could be included in the meta-analysis if they were not part of the collaboration, and the trials included, if done many years ago, might not reflect contemporary management. More research in older people is needed to enrich the evidence on the risks and benefits of statins.
No drug is completely harmless. When statins are used in people with low cardiovascular risk, the risks and benefits need to be weighed against each other. Statins have been associated with a slight increase in incidence of muscle pain, diabetes, and haemorrhagic stroke, but their benefits in prevention of major vascular events are shown to be much greater. 6 The present meta-analysis that includes people older than standard trial populations echoes this conclusion. 7 The challenge for the health-care profession and the media is to convey risks and benefits in ways that patients can understand, enabling them to make an informed choice.
component of the extracellular matrix surrounding the oocyte-cumulus complex. The biological rationale behind PICSI is that sperm that bind to hyaluronan are of better quality than those that do not, resulting in better quality embryos when used for ICSI and thus an increased chance of livebirth. ]; 0·61, 0·43-0·84; p=0·003). Given that the authors did not provide data on the number of embryos generated or embryo quality, it is unclear whether and how this effect on miscarriage was mediated by PICSI. A potential alternative explanation, although purely hypothetical, is that the embryologists, who were not masked to the allocated treatment for obvious reasons, had a preference or belief in PICSI that led them to be less precise when selecting the right sperm to be injected in the standard ICSI group.
Despite these reservations, the authors should be applauded for doing such a well designed trial, which yet again shows the lack of clinical benefit for a so-called add-on to IVF treatment. Robust clinical trials have previously reported no benefit for other promising IVF add-ons, such as preimplantation genetic screening 5 and endometrial scratching (ACTRN12614000626662). In fact, as evidenced by two reviews of available treatments for subfertility, 6, 7 data demonstrating benefit are lacking for the vast majority of fertility treatments, thus calling into question their routine clinical use.
So why are these treatments offered? The answer is not a pretty one. Increasingly, the field of assisted reproductive technologies is a commercial endeavour wherein couples who are unable to become pregnant are lured into treatments that are of claimed benefit for them. Websites of fertility clinics claim benefits but do not provide data or references that support these claims. 8 Moreover, websites often display so-called success rates, but the way that these are presented is far from uniform and allows for substantial selective reporting. 9 Increasing investment in assisted reproduction comes from venture capital, and multibillion companies are buying clinics and suppliers of pharmaceutical drugs and laboratory products. And of course, these companies and their shareholders want a return on their investment.
So how to proceed? The way forward is simply to do more randomised clinical trials, such as now performed for PICSI. 4, 10 Now more than ever, we need to apply the principles of evidence-based medicine to reproductive medicine to allow for "the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients". 11 Additionally, governing bodies, such as the Human Fertilisation and Embryology Authority and the European Society of Human Reproduction and Embryology, should increase their efforts to force clinics to present accurate information and to protect patients from treatments of unknown benefit and, even more important, from treatments of no known benefit. In countries with national health-care insurance that covers fertility treatments, insurance companies should refrain from subsidising treatments that are of unknown benefit unless such treatments are offered in the context of a properly designed clinical trial. Only in this way will couples be safeguarded from those with a commercial interest who strive for a return on investment above a proven benefit for patients. 
Does bovine lactoferrin prevent late-onset neonatal sepsis?
Prevention of late-onset neonatal sepsis (LOS) in infants born very preterm (<32 weeks' gestation) is paramount because of its associated mortality and morbidity. Lactoferrin has antimicrobial properties and could be preventive. 1 Lactoferrin concentrations in human breastmilk vary little with gestational age and fall over time after birth; 2 they are lower in infant formulas. 3 Importantly, very preterm infants have low enteral intakes in the first days after birth, and this can persist for weeks. Consequently, infants born very preterm might benefit from supplemental lactoferrin to prevent LOS.
In a 2017 Cochrane review, 4 enteral lactoferrin was found not only to reduce the rate of any LOS (risk ratio [RR] 0·59, 95% CI 0·40-0·87; p=0·008; from six trials including 886 participants) but also of necrotising enterocolitis (0·40, 0·18-0·86; p=0·02; from four trials including 750 participants). Five randomised controlled trials (RCTs) assessed bovine lactoferrin and one tested human recombinant lactoferrin. However, the quality of all the included studies was low. The authors of the review made no recommendation to introduce bovine lactoferrin into clinical practice.
In The Lancet, the ELFIN Trial Investigators Group reports its large multicentre RCT, 5 which was designed to address the limitations of the existing evidence in the use of bovine lactoferrin to prevent LOS. They recruited 2203 infants born at less than 32 weeks' gestation and younger than 72 h from 37 sites around the UK in just under 3·5 years. Infants were randomly allocated to receive either bovine lactoferrin (150 mg/kg daily, once the infants were receiving at least 12 mL/kg per day enterally) or an equal volume of sucrose placebo until 34 weeks' gestation. Bovine lactoferrin had little effect on the primary endpoint of LOS (316 [29%] of 1093 infants in the lactoferrin group and 334 [31%] of 1089 in the control group developed LOS; adjusted RR 0·95, 95% CI 0·86-1·04; p=0·233). Importantly, lactoferrin had little effect on other clinically important outcomes including mortality (1·05, 0·66-1·68; p=0·782) and the combined outcome of mortality with LOS, necrotising enterocolitis, or bronchopulmonary dysplasia (1·01, 0·94-1·08; p=0·743).
The study design and governance appear exemplary. Infants were at equal risk of reaching the endpoint through randomisation, other clinical care was equal because of effective blinding, the primary clinically important outcome of LOS was known for all but 1% (n=23) of those enrolled, the infants were representative of very preterm infants in high-income countries, and treatment compliance was excellent. Moreover, they reported other clinically important outcomes including mortality, necrotising enterocolitis, bronchopulmonary dysplasia, and retinopathy of prematurity, and the combined outcome of death with any LOS, necrotising enterocolitis, bronchopulmonary
